Sep. 9 at 8:59 PM
$VERA Advancement in the standard of care would be significant if Ataticept is approved. Kidney failure is all to often the outcome of IgA Nephropathy. The Ph. 3 ORIGIN primary endpoint met at 36 weeks, showed “better or similar” results than ORIGIN 2b. Already in discussions with FDA for BLA submission, hopes of an accelerated approval and then launch in 2026. What this could offer are profound changes to eliminate dialysis or transplantation in patients who suffer from this condition. In listening to their presentation last week you can tell they are excited by the science and the results so far. Let’s go!
